154632-86-7

Upstream product

• 501-53-1 benzyl chloroformate 
• 160233-42-1 (2R)-1-tritylaziridine-2-carboxylic acid methyl ester 
• 67-56-1 methanol 
• 1103830-29-0 (R)-1-[{(1'-Benzyloxycarbonyl)aziridin-2'-yl}carbonyl]-3,5-dimethyl-1H-pyrazole 
• 103539-32-8 (2R)-aziridine-2-carboxylic acid methyl ester 

Downstream Products

• 161253-87-8 (R)-2-Benzyloxycarbonylamino-3-(2-methyl-1H-indol-3-yl)-propionic acid 
• 161253-78-7 (S)-2-{(R)-2-[((S)-1-{(R)-2-[(R)-2-Benzyloxycarbonylamino-3-(2-methyl-1H-indol-3-yl)-propionylamino]-3-methoxycarbonyl-propionyl}-pyrrolidine-2-carbonyl)-amino]-2-cyclopentyl-acetylamino}-4-methyl-pentanoic acid benzyl ester 
• 103539-32-8 (2R)-aziridine-2-carboxylic acid methyl ester 
• 209804-17-1 (R)-2-Benzyloxycarbonylamino-3-methoxy-propionic acid methyl ester 
• 93204-37-6 (2R)-2-(benzyloxycarbonylamino)-3-tert-butoxypropionic acid methyl ester 
• 1017575-35-7 methyl N-benzyloxycarbonyl-O-(2-((tert-butoxycarbonyl)(4-methoxybenzyl)amino)ethyl)-D-serinate 
• 783368-22-9 methyl N-[(benzyloxy)carbonyl]-O-{(1S)-2-[(tert-butoxycarbonyl)(cyclopropylmethyl)amino]-1-phenylethyl}-D-serinate 
• 21149-17-7 methyl 2-(benzyloxycarbonylamino)acrylate 
• 161253-88-9 (R)-2-Benzyloxycarbonylamino-3-(2-methyl-1H-indol-3-yl)-propionic acid methyl ester 

Relevant academic research and scientific papers

Aryl substituted aminotetrahydropyran compound and use thereof

The invention relates to an aryl substituted aminotetrahydropyran compound and use thereof, and further relates to a pharmaceutical composition comprising the compound. The compound or pharmaceuticalcomposition provided by the invention can be used as a dipeptidyl peptidase-IV (DPP-IV) inhibitor.

PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF DIABETES OR OBESITY COMPRISING A COMPOUND THAT INHIBITS ACTIVITY OF DIPEPTIDYL PEPTIDASE-IV, AND OTHER ANTIDIABETIC OR ANTIOBESITY AGENTS AS ACTIVE INGREDIENTS

The present invention relates to a pharmaceutical composition for the prevention and treatment of diabetes or obesity comprising as active ingredients a compound which inhibits the activity of dipeptidyl peptidase-IV(DPP-IV), a pharmaceutically acceptable

Catalytic aziridination of electron-deficient olefins with an N-chloro-N-sodio carbamate and application of this novel method to asymmetric synthesis

A new method for the aziridination of electron-deficient olefins using an N-chloro-N-sodio carbamate is described; the reaction was promoted by phase-transfer catalysis (solid-liquid) and afforded aziridines from α,β-unsaturated ketones, esters, sulfones and amides. The Royal Society of Chemistry 2008.

DPP-IV INHIBITOR INCLUDING BETA-AMINO GROUP, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR PREVENTING AND TREATING A DIABETES OR AN OBESITY

The present invention provides a novel heterocyclic compound containing a beta-amino group, a method for preparing the same, and a pharmaceutical composition comprising the same heterocyclic compound or a pharmaceutically acceptable salt thereof as an act

Efficient synthesis of (6R)-6-amino-1-methyl-4-(3-methylbenzyl)-hexahydro-1H-1,4-diazepine from methyl (2R)- and (2S)-1-benzyloxycarbonylaziridine-2-carboxylates

An efficient and practical method for the synthesis of (6R)-6-amino-1-methyl-4-(3-methylbenzyl)hexahydro-1H-1,4-diazepine 2, which serves as the amine part of DAT-582, a potent and selective 5-HT3 receptor antagonist, is described. The key inte

Versatile Synthesis of Stereospecifically Labelled D-Amino Acids via Labelled Aziridines - Preparation of (2R,3S)-- and (2R,3R)--Serine; (2S,2'S,3S,3'S)-- and (2S,2'S,3R,3'R)--Cystine; and (2S,3S)- and (2S,3R)--β-Chloroalanine

Stereospecifically β-labelled protected 2-carboxyaziridines 2, with the stereochemistry of a D-amino acid at C-2, have been prepared by a chemicoenzymic synthesis.Preparation of the labelled malates 5, by hydration of fumaric acid using the enzyme fumarase or by amination with aspartase followed by nitrosation, was followed by conversion into the isoserines 3, by a process involving Curtius rearrangement with retention of stereochemistry at the chirally labelled primary centre.Protection and ring closure gave the aziridines 2, which, on ring opening with the appropriate nucleophiles and deprotection, gave stereospecifically labelled samples of D-serine 16, D-cystine 20 and β-chloro-D-alanine 22.